Vγ9Vδ2 T cells strengthen cisplatin inhibition activity against breast cancer MDA-MB-231 cells by disrupting mitochondrial function and cell ultrastructure

BACKGROUND: Breast cancer ranks second of new cases and fifth of death in 2018 worldwide. Cis-platinum (CDDP) has been used as a chemotherapy to treat breast cancer for years. However, CDDP can adversely disrupt immune function of host. Thus, development of new protocol that can minimize side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xin, Wang, Cunchuan, Wang, Ningxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885429/
https://www.ncbi.nlm.nih.gov/pubmed/33593340
http://dx.doi.org/10.1186/s12935-021-01815-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885429/
https://www.ncbi.nlm.nih.gov/pubmed/33593340
http://dx.doi.org/10.1186/s12935-021-01815-0

Ejemplares similares